Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Barinthus Biotherapeutics (BRNS) Non-Current Assets (2020 - 2025)

Barinthus Biotherapeutics' Non-Current Assets history spans 6 years, with the latest figure at $20.4 million for Q4 2025.

  • For Q4 2025, Non-Current Assets fell 41.08% year-over-year to $20.4 million; the TTM value through Dec 2025 reached $104.1 million, down 47.93%, while the annual FY2025 figure was $20.4 million, 41.08% down from the prior year.
  • Non-Current Assets reached $20.4 million in Q4 2025 per BRNS's latest filing, down from $22.4 million in the prior quarter.
  • In the past five years, Non-Current Assets ranged from a high of $61.4 million in Q2 2023 to a low of $3.1 million in Q2 2021.
  • Average Non-Current Assets over 5 years is $42.1 million, with a median of $54.5 million recorded in 2024.
  • Peak YoY movement for Non-Current Assets: skyrocketed 1851.18% in 2021, then plummeted 58.51% in 2025.
  • A 5-year view of Non-Current Assets shows it stood at $54.0 million in 2021, then increased by 5.96% to $57.2 million in 2022, then grew by 0.76% to $57.6 million in 2023, then tumbled by 39.96% to $34.6 million in 2024, then tumbled by 41.08% to $20.4 million in 2025.
  • Per Business Quant, the three most recent readings for BRNS's Non-Current Assets are $20.4 million (Q4 2025), $22.4 million (Q3 2025), and $29.1 million (Q2 2025).